593 related articles for article (PubMed ID: 18539963)
21. State of the science: molecular classifications of breast cancer for clinical diagnostics.
Robison JE; Perreard L; Bernard PS
Clin Biochem; 2004 Jul; 37(7):572-8. PubMed ID: 15234238
[TBL] [Abstract][Full Text] [Related]
22. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
23. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
[TBL] [Abstract][Full Text] [Related]
24. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection.
Broët P; Camilleri-Broët S; Zhang S; Alifano M; Bangarusamy D; Battistella M; Wu Y; Tuefferd M; Régnard JF; Lim E; Tan P; Miller LD
Cancer Res; 2009 Feb; 69(3):1055-62. PubMed ID: 19176396
[TBL] [Abstract][Full Text] [Related]
25. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
26. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
Correa Geyer F; Reis-Filho JS
Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
[TBL] [Abstract][Full Text] [Related]
27. [Developments in cancer care with innovative genomics. 2008 report of the National Cancer Consortium].
Tímár J; Kásler M; Heringh A; Soós M; Mathiász D; Romány A; Józsa A; Szilák L; Forrai T; Patthy L; Kovács G
Magy Onkol; 2009 Dec; 53(4):321-34. PubMed ID: 20071304
[TBL] [Abstract][Full Text] [Related]
28. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
McDermott U; Settleman J
J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
[TBL] [Abstract][Full Text] [Related]
29. Global mRNA analysis to determine a transcriptome profile of cancer stemness in a mouse model.
Heffron CC; Gallagher MF; Guenther S; Sherlock J; Henfrey R; Martin C; Sheils O; O'Leary JJ
Anticancer Res; 2007; 27(3A):1319-24. PubMed ID: 17593625
[TBL] [Abstract][Full Text] [Related]
30. Lung cancer: future directions.
Lam WK; Watkins DN
Respirology; 2007 Jul; 12(4):471-7. PubMed ID: 17587411
[TBL] [Abstract][Full Text] [Related]
31. Molecular classification of human carcinomas by use of gene expression signatures.
Su AI; Welsh JB; Sapinoso LM; Kern SG; Dimitrov P; Lapp H; Schultz PG; Powell SM; Moskaluk CA; Frierson HF; Hampton GM
Cancer Res; 2001 Oct; 61(20):7388-93. PubMed ID: 11606367
[TBL] [Abstract][Full Text] [Related]
32. Defining the steps that lead to cancer: replicative telomere erosion, aneuploidy and an epigenetic maturation arrest of tissue stem cells.
Stindl R
Med Hypotheses; 2008; 71(1):126-40. PubMed ID: 18294777
[TBL] [Abstract][Full Text] [Related]
33. Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model.
Rhee DK; Park SH; Jang YK
Genomics; 2008 Dec; 92(6):419-28. PubMed ID: 18804527
[TBL] [Abstract][Full Text] [Related]
34. Why most gene expression signatures of tumors have not been useful in the clinic.
Koscielny S
Sci Transl Med; 2010 Jan; 2(14):14ps2. PubMed ID: 20371465
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
36. Expression profiling and individualisation of treatment for ovarian cancer.
Agarwal R; Kaye SB
Curr Opin Pharmacol; 2006 Aug; 6(4):345-9. PubMed ID: 16750423
[TBL] [Abstract][Full Text] [Related]
37. Women's interest in gene expression analysis for breast cancer recurrence risk.
O'Neill SC; Brewer NT; Lillie SE; Morrill EF; Dees EC; Carey LA; Rimer BK
J Clin Oncol; 2007 Oct; 25(29):4628-34. PubMed ID: 17925559
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Bild AH; Yao G; Chang JT; Wang Q; Potti A; Chasse D; Joshi MB; Harpole D; Lancaster JM; Berchuck A; Olson JA; Marks JR; Dressman HK; West M; Nevins JR
Nature; 2006 Jan; 439(7074):353-7. PubMed ID: 16273092
[TBL] [Abstract][Full Text] [Related]
39. Genomics in breast cancer-therapeutic implications.
Lønning PE; Sørlie T; Børresen-Dale AL
Nat Clin Pract Oncol; 2005 Jan; 2(1):26-33. PubMed ID: 16264853
[TBL] [Abstract][Full Text] [Related]
40. A six-gene signature predicting breast cancer lung metastasis.
Landemaine T; Jackson A; Bellahcène A; Rucci N; Sin S; Abad BM; Sierra A; Boudinet A; Guinebretière JM; Ricevuto E; Noguès C; Briffod M; Bièche I; Cherel P; Garcia T; Castronovo V; Teti A; Lidereau R; Driouch K
Cancer Res; 2008 Aug; 68(15):6092-9. PubMed ID: 18676831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
